Research Library

State "right to try" laws can give terminally ill patients early access to experimental drugs and medical devices — but they arguably make safety and efficacy secondary to speedy access.

The core strategies of the U.S. War on Drugs are eradication, interdiction and incarceration. After a 40-year and trillion-dollar effort, illicit drugs remain available to meet a remarkably stable demand. Drawing on decades of government-gathered and publicly available data, William Martin, director of the Drug Policy Program, and contributing expert Jerry Epstein contend that U.S. drug policy is premised on incorrect assumptions, aims at the wrong targets and can never succeed. But because these data run counter to a century of anti-drug propaganda, they play only a small role in public policy, mass-media presentation and popular perception. In this policy report, Martin and Epstein call for a reexamination of the data and sweeping revision of existing strategies. They urge formation of a politically independent national scientific commission, its members chosen by the National Academy of Sciences, in consultation with the NIH and the Department of Health and Human Services, to facilitate open examination and honest consideration of alternatives to current failed or flawed policies.

This report suggests the contours of a more comprehensive policy for the United States in the broader Middle East, one that pursues not only important tactical approaches to counter Islamic extremism and terrorism, but also shapes the larger strategic landscape to secure and promote U.S. interests. After defining the challenge for the United States and the international community, the report provides a brief narrative on the rise of ISIS before presenting key policy recommendations for a more strategic approach.

Stem cells from umbilical cord blood (CB) can be used to treat over 80 different diseases, including many types of leukemia, lymphoma and inherited immune system disorders. Extensive storage facilities in the United States and around the world collect, test and freeze CB for later use in medical procedures. However, the divide between two different banking models — public versus private — presents policy challenges. This policy report examines the difference between public and private cord blood banks and offers recommendations for US policymakers to improve cord blood banking and ensure high quality standards.